Zydus Lifesciences is trading at RS. 1040.65, up by 3.65 points or 0.35% from its previous close of RS. 1037.00 on the BSE.

The stock opened at RS. 1039.75 and touched a high of RS. 1042.00 and a low of RS. 1033.75. So far, 4804 shares have been traded on the counter.

The BSE group 'A' stock, with a face value of RS. 1, has recorded a 52-week high of RS. 1087.80 on September 30, 2024, and a 52-week low of RS. 797.05 on April 7, 2025. Over the last week, the scrip’s high and low stood at RS. 1059.00 and RS. 1025.30, respectively. The company’s current market capitalization is RS. 104281.06 crore.

Promoters hold 74.99% of the company’s shares, while institutions and non-institutions hold 18.26% and 6.74%, respectively.

Zydus Lifesciences has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for a GMP follow-up inspection at its oncology injectable facility located at SEZ1, Ahmedabad. The inspection was conducted between June 9 and June 18, 2025, and the facility has now been classified as Voluntary Action Indicated (VAI).

This marks an improvement from June 2024 when the facility was classified as Official Action Indicated (OAI).

Formerly known as Cadila Healthcare, Zydus Lifesciences is an integrated pharmaceutical company in India engaged in research, development, production, marketing, and distribution across the pharmaceutical value chain.